Drug Trial Radar · NCT01015118
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
Last checked: Nov 20, 2026Latest source record: Dec 7, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,366
Actual
Start
Nov 17, 2009
Primary completion
Apr 1, 2013
Study completion Sep 15, 2016
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Nov 18, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced ovarian cancer. Safety information about BIBF1120/paclitaxel/carboplatin will be obtained.
Conditions
- Ovarian Neoplasms
- Peritoneal Neoplasms
Interventions
PlaceboDrug
comparator to BIBF 1120
PaclitaxelDrug
Paclitaxel (standard chemo-therapy)
BIBF 1120Drug
comparison of BIBF 1120 in combination with chemotherapy and placebo in combination with chemotherapy (paclitaxel/carboplatin)
CarboplatinDrug
Carboplatin (standard chemo-therapy)
PaclitaxelDrug
Paclitaxel (standard chemo-therapy)
CarboplatinDrug
Carboplatin (standard chemo-therapy)
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria.Time frame: First drug administration to date of disease progression or death whichever occurs first , upto 29 months
- PFS Based on Investigator Assessment According to Modified Response Evaluation Criteria in Solid Tumors, Version 1.1 (mRECIST), and Additional Clinical Criteria (Follow up Analysis).Time frame: First drug administration to date of disease progression or death whichever occurs first until final Data Base Lock (DBL) 26September16, upto 62 months
Locations
281 sites in 22 countries. Site status is shown where the registry gives one.
1199.15.10113 Boehringer Ingelheim Investigational Site
Tucson, Arizona
1199.15.10030 Boehringer Ingelheim Investigational Site
Long Beach, California
1199.15.10001 Boehringer Ingelheim Investigational Site
Santa Rosa, California
1199.15.10005 Boehringer Ingelheim Investigational Site
Englewood, Colorado
1199.15.10028 Boehringer Ingelheim Investigational Site
New Haven, Connecticut
1199.15.10014 Boehringer Ingelheim Investigational Site
Orlando, Florida
1199.15.10010 Boehringer Ingelheim Investigational Site
Augusta, Georgia
1199.15.10004 Boehringer Ingelheim Investigational Site
Savannah, Georgia
1199.15.10011 Boehringer Ingelheim Investigational Site
Louisville, Kentucky
1199.15.10003 Boehringer Ingelheim Investigational Site
Marrero, Louisiana
1199.15.10017 Boehringer Ingelheim Investigational Site
Detroit, Michigan
1199.15.10103 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota
1199.15.10002 Boehringer Ingelheim Investigational Site
New York, New York
1199.15.10012 Boehringer Ingelheim Investigational Site
Charlotte, North Carolina
1199.15.10020 Boehringer Ingelheim Investigational Site
Winston-Salem, North Carolina
1199.15.10019 Boehringer Ingelheim Investigational Site
Bismarck, North Dakota
1199.15.10024 Boehringer Ingelheim Investigational Site
Canton, Ohio
1199.15.10025 Boehringer Ingelheim Investigational Site
Cleveland, Ohio
1199.15.10029 Boehringer Ingelheim Investigational Site
Cleveland, Ohio
1199.15.10021 Boehringer Ingelheim Investigational Site
Portland, Oregon
1199.15.10013 Boehringer Ingelheim Investigational Site
Abington, Pennsylvania
1199.15.10016 Boehringer Ingelheim Investigational Site
Allentown, Pennsylvania
1199.15.10008 Boehringer Ingelheim Investigational Site
Providence, Rhode Island
1199.15.10102 Boehringer Ingelheim Investigational Site
Greenville, South Carolina
1199.15.10006 Boehringer Ingelheim Investigational Site
Chattanooga, Tennessee
1199.15.10104 Boehringer Ingelheim Investigational Site
Austin, Texas
1199.15.10100 Boehringer Ingelheim Investigational Site
Bedford, Texas
1199.15.10107 Boehringer Ingelheim Investigational Site
Dallas, Texas
1199.15.10108 Boehringer Ingelheim Investigational Site
Dallas, Texas
1199.15.10110 Boehringer Ingelheim Investigational Site
Fort Worth, Texas
1199.15.10007 Boehringer Ingelheim Investigational Site
Houston, Texas
1199.15.10105 Boehringer Ingelheim Investigational Site
Spokane, Washington
1199.15.10112 Boehringer Ingelheim Investigational Site
Vancouver, Washington
1199.15.61006 Boehringer Ingelheim Investigational Site
Camperdown, New South Wales, Australia
1199.15.61001 Boehringer Ingelheim Investigational Site
Waratah, New South Wales, Australia
1199.15.61004 Boehringer Ingelheim Investigational Site
Herston, Queensland, Australia
1199.15.61003 Boehringer Ingelheim Investigational Site
Southe Brisbane, Queensland, Australia
1199.15.61005 Boehringer Ingelheim Investigational Site
North Terrace, South Australia, Australia
1199.15.61007 Boehringer Ingelheim Investigational Site
Parkville, Victoria, Australia
1199.15.61002 Boehringer Ingelheim Investigational Site
Nedlands, Western Australia, Australia
Showing 40 of 281 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.